

Mydriasis - Pipeline Insight, 2021

<https://marketpublishers.com/r/M1373C24270EEN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: M1373C24270EEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Mydriasis – Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Mydriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Mydriasis Understanding

Mydriasis: Overview

Mydriasis is the medical term for an unusual dilation or widening of the pupils. This may be caused by an injury, psychological factors, or due to the uptake of certain drugs or medications. The characteristic symptom of mydriasis is dilated pupils that do not get bigger or smaller in response to changes in light. When the pupils are dilated, the eyes become more sensitive to light. This can lead to blurry vision, as well as, in some cases, a general feeling of constriction around the forehead and eyes. Treatment approaches try to protect the full functionality of the eyes and generally depends on what caused the condition in first.

'Mydriasis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed

picture of the Mydriasis pipeline landscape is provided which includes the disease overview and Mydriasis treatment guidelines. The assessment part of the report embraces, in depth Mydriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mydriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Mydriasis R&D. The therapies under development are focused on novel approaches to treat/improve Mydriasis.

Mydriasis Emerging Drugs Chapters

This segment of the Mydriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mydriasis Emerging Drugs

Phentolamine Ophthalmic Solution: Ocuphire Pharma, Inc.

Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors leading to a muscle relaxation and a widening of the blood vessels. The phentolamine ophthalmic solution is being evaluated in phase III stage of development for the treatment of Mydriasis.

Further product details are provided in the report.....

Mydriasis: Therapeutic Assessment

This segment of the report provides insights about the different Mydriasis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Mydriasis

There are approx. 5+ key companies which are developing the therapies for Mydriasis. The companies which have their Mydriasis drug candidates in the most advanced stage, i.e. phase III include, Ocuphire Pharma, Inc.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Mydriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Bispecific Antibody

Peptides

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mydriasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mydriasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mydriasis drugs.

Mydriasis Report Insights

Mydriasis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Mydriasis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Mydriasis drugs?

How many Mydriasis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mydriasis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mydriasis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Mydriasis and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

- Introduction
- Executive Summary
- Mydriasis: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Mydriasis – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Mydriasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Mydriasis Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Phentolamine Ophthalmic Solution: Ocuphire Pharma
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- EYN-1601: Eyenovia, Inc.
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....

Preclinical Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Mydriasis Key Companies

Mydriasis Key Products

Mydriasis- Unmet Needs

Mydriasis- Market Drivers and Barriers

Mydriasis- Future Perspectives and Conclusion

Mydriasis Analyst Views

Mydriasis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Mydriasis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Mydriasis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Mydriasis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/M1373C24270EEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M1373C24270EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970